Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
NCT07237659
This study is recruiting at 7 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are: What is the highest dose of NTR-1011 that is safe and well tolerated, when given under the skin or into a vein? How does the body process NTR-1011, and how does NTR-1011 affect the body? Does the body develop an immune response to NTR-1011?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SLE (Systemic Lupus)
- RA - Rheumatoid Arthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Neutrolis
- Last updated on ClinicalTrials.gov
- July 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 7
- Carewell Arthritis Center · Apple Valley, CA
- Attune Health Research Inc · Beverly Hills, CA
- Covina Arthritis Clinic · Covina, CA
- Novamed · Monterey Park, CA
- Southland Arthritis Clinic · Riverside, CA
- Southland Arthritis Clinic · Temecula, CA
- Foothill Arthritis Clinic · Tujunga, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.